Skip to main content

Table 2 Estimated gestational age and time to recurrence of Plasmodium falciparum (Pf) for novel and recrudescent infections for each anti-malarial treatment and including the distribution of intercalated Plasmodium vivax infections

From: Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort

  EGAd (weeks) Time to novel infection (days) Time to recrudescent infection (days) Intercalated P. vivax
Anti-malarial (action, years)a Nb Median [range] N Median [range] N Median [range] % >28 days % >42 days % >63 days % (N)c
Quinine monotherapy (short, 1994–2006) 476 17 [3–36] 173 47 [7–216] 303 21 [7–126] 25.4 (77/303) 10.6 (32/303) 5.0 (15/303) 33.0 (58)
Quinine + clindamycin (short, 1998–2009) 29 10 [4–24] 22 84 [28–201] 7 50 [21–122] 57.1 (4/7) 57.1 (4/7) 42.9 (3/7) 7.4 (13)
Artesunate monotherapy (short, 1995–2008) 151 21 [4–37] 102 54 [8–182] 49 22 [11–99] 30.6 (15/49) 12.2 (6/49) 4.1 (2/49) 21.6 (38)
Artesunate + Clindamycin (short, 1998–2009) 143 23e [1–39] 121 49 [21–158] 22 28 [12–70] 45.5 (10/22) 27.3 (6/22) 9.1 (2/22) 26.1 (46)
Artemether + lumefantrine (medium, 2004–2006) 43 23 [13–36] 24 36 [15–140] 19 23 [14–63] 31.6 (6/19) 26.3 (5/19) 0.0 (0/19) 6.3 (11)
Artesunate + Atovaquone + proguanil (medium, 1999–2005) 11 23 [18–32] 8 67 [44–101] 3 49 [35–120] 100.0 (3/3) 66.7 (2/3) 33.3 (1/3) 1.7 (3)
Mefloquine monotherapy (long, 1994–1997) 22 26 [12–38] 4 25 [9–44] 18 22 [7–123] 27.8 (5/18) 5.6 (1/18) 5.6 (1/18) 0 (0)
DHAf + Piperaquine (long, 2006–2008) 29 20 [8–34] 23 63 [35–180] 6 33 [21–49] 66.7 (4/6) 16.7 (1/6) 0.0 (0/6) 4.0 (7)
Artesunate + Mefloquine (long, 1995–2008) 5 28 [−0.4-39] 4 35 [20–43] 1 21 [−] 0.0 (0/1) 0.0 (0/1) 0.0 (0/1) 0 (0)
  1. aaction, reflects length of time anti-malarial remains in the body after administration; years, period in which treatment was administered at SMRU
  2. bN, number of recurrent Pf episodes
  3. c% (N), percentage and number of intercalated P. vivax episodes
  4. dEGA, estimated gestational age (weeks) at time of malaria episode
  5. eone EGA missing
  6. fDHA, dihydroartemisinin